Search
Litifilimab
go.drugbank.com/drugs/DB18864InvestigationalLitifilimab is under investigation in clinical trial NCT05531565 (A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus ( … SCLE) And/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory And/or Intolerant to Antimalarial Therapy).
Rivoglitazone
go.drugbank.com/drugs/DB09200InvestigationalRivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co.
PT-2385
go.drugbank.com/drugs/DB16055InvestigationalPT-2385 is under investigation in clinical trial NCT03108066 (PT2385 for the Treatment of Von Hippel-lindau Disease-associated Clear Cell Renal Cell Carcinoma).
GED-0507-34-Levo
go.drugbank.com/drugs/DB16109InvestigationalGED-0507-34-Levo is under investigation in clinical trial NCT02808390 (Efficacy and Safety Study of Ged-0507-34-levo for Treatment of UC).
AUM-601
go.drugbank.com/drugs/DB17382ExperimentalAUM-601 is a highly selective pan-TRK(tropomyosin receptor kinase). It is currently being investigated in clinical trials for the treatment of cancer.
VAD-044
go.drugbank.com/drugs/DB17697InvestigationalVAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.[L46098]
MOR-22
go.drugbank.com/drugs/DB17790ExperimentalMOR-22, a Natural human lymphoblastoid interferon-alpha, is currently being investigated to treat papillomavirus warts in the oral cavity of HIV-positive patients.
NDX-3315
go.drugbank.com/drugs/DB18671InvestigationalNDX-3315 is an investigational radiopharmaceutical agent for the diagnosis, treatment monitoring, and management of eosinophilic esophagitis. It is a technetium-99m radiolabeled [heparin].
Oxantel
go.drugbank.com/drugs/DB13670InvestigationalOxantel is an anthelmintic drug that targets parasitic acetylcholine receptors.[A275093, A275098]
Lisavanbulin
go.drugbank.com/drugs/DB15224InvestigationalLisavanbulin is under investigation in clinical trial NCT02895360 (Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma).